The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
KMOV St. Louis on MSN10h
Nasal COVID vaccine developed at WashU approved for clinical trialsThe Food and Drug Administration (FDA) recently gave approval for clinical trials in the U.S. of a COVID-19 nasal vaccine ...
Hopkins researchers help secure full FDA approval to treat immunocompromised COVID-19 patients—paving the way to explore ...
A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...
The U.S. Food and Drug Administration has approved the first-ever clinical trials testing pig kidney transplants in people ...
GlobalData on MSN4d
Celltrion’s Avtozma receives FDA approval for multiple conditionsThe FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.
PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 ...
After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...
On January 17, the Drug Enforcement Administration (DEA) and the U.S. Department of Health and Human Services (HHS) jointly published two final ...
Revive Therapeutics Ltd. ("Revive” or the "Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback